课题基金 / 基金详情

CLINICAL TRIAL: A PHASE II STUDY OF PN401 PYRIMIDINE RESPONSIVE SYNDROME OF NEUR

CLINICAL TRIAL: A PHASE II STUDY OF PN401 PYRIMIDINE RESPONSIVE SYNDROME OF NEUR
临床试验：PN401 嘧啶反应性神经综合征综合征的 II 期研究
批准号：
7724883
负责人：
BRUCE A BARSHOP
金额：
$0.14万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
项目状态：
已结题
起止时间：
2007-12-01 至 2008-11-30
来源：
https://reporter.nih.gov/project-details/7724883
关键词：
Clinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseFundingGrantInfectionInstitutionLanguageNeurologic DysfunctionsPN401 (triacetyluridine)PatientsPhasePredispositionPyrimidinePyrimidinesQuality of lifeResearchResearch PersonnelResourcesSafetySeizuresSigns and SymptomsSourceSpeechSyndromeUnited States National Institutes of Healthcognitive function

项目摘要

项目成果

BRUCE A BARSHOP的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 评估PN401在减少癫痫发作和感染、改善具有神经功能障碍和感染易感性的嘧啶反应综合征患者的言语、语言和认知功能方面的安全性和有效性，评估生活质量，并描述PN401对该综合征体征和症状的影响。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Evaluate safety and efficacy of PN401 in reduction of seizures and infections, improvement of speech and language and cognitive functions in patients with pyrimidine responsive syndrome of neurological dysfunction and susceptibility to infection, evaluate quality of life, and describe effects of PN401 on signs and symptoms of the syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CYSTEAMINE BITARTRATE DELAYED-RELESEASE CAPSULES (RP103) COMPARED TO CYSTEAMINE
CLINICAL TRIAL: A PHASE II STUDY OF PN401 PYRIMIDINE RESPONSIVE SYNDROME OF NEUR
CLINICAL TRIAL: ALGLUCOSIDASE ALFA TEMPORARY ACCESS PROGRAM (ATAP) PROTOCOL AGLU
CLINICAL TRIAL: A PHASE II STUDY OF PN401 PYRIMIDINE RESPONSIVE SYNDROME OF NEUR